Katz D N
CRNA. 1992 May;3(2):54-63.
Malignant hyperthermia (MH) is an uncommon and potentially fatal pharmacogenetic complication of anesthesia. It is commonly triggered by administration of halothane and succinylcholine. The treatment of choice is to administer dantrolene sodium while simultaneously discontinuing the triggering agent. The continued treatment of the patient will reflect the hypermetabolic state. Anesthesia can be safely administered to MH-susceptible patients. Nontriggering agents are used, and meticulous monitoring of the patient is performed. All anesthesia providers should be familiar with MH.
恶性高热（MH）是一种罕见且可能致命的麻醉药物遗传并发症。它通常由氟烷和琥珀酰胆碱的给药引发。首选的治疗方法是给予丹曲林钠，同时停用引发药物。对患者的持续治疗将反映其高代谢状态。可以安全地对恶性高热易感患者实施麻醉。使用非引发药物，并对患者进行细致监测。所有麻醉医护人员都应熟悉恶性高热。
